Orforglipron, also known as LY3502970 or OWL 833, is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that is being developed by the pharmaceutical company Eli Lilly. This oral medication can help improve blood sugar levels and promote weight loss, making it beneficial for people with diabetes mellitus and obesity.
As a glucagon-like peptide-1 receptor agonist (GLP-1RA), orforglipron increases the release of insulin from the pancreas by increasing the volume of insulin-producing beta cells and reducing the release of glucagon (a hormone that increases blood sugar levels). Orforglipron also promotes weight loss by slowing the movement of food (peristalsis) from the stomach into the small intestine, resulting in increased feelings of fullness and reduced food intake. In the liver, it also decreases the production of blood sugar (glucose) and fat content. Orforglipron also improves heart health by increasing the secretion of natriuretic peptides which play an essential role in maintaining cardiovascular homeostasis or balance. In the brain, orforglipron can help improve cognitive function by protecting against nerve damage and enhancing the transmission of nerve signals.
As a glucagon-like peptide-1 receptor agonist (GLP-1RA), orforglipron promotes weight loss by slowing the movement of food (peristalsis) from the stomach into the small intestine (gastric emptying). This in turn results in increased feelings of fullness. With increased satiety, the food intake is reduced while the energy expenditure is increased, resulting in weight loss.
Evidence shows that orforglipron has fat-burning properties and is beneficial for people with obesity:
Orforglipron can also help normalize elevated blood sugar levels. As a glucagon-like peptide-1 receptor agonist (GLP-1RA), orforglipron increases the release of insulin from the pancreas by increasing the volume of insulin-producing beta cells. With increased insulin, blood sugar can enter the cells easily to allow for efficient energy usage. This means that the body can effectively utilize blood sugar as a source of energy for various important functions. In addition, orforglipron can also reduce high blood sugar levels by reducing the release of glucagon and decreasing the production of blood sugar (glucose) and fat content in the liver.
The blood sugar-lowering effects of orforglipron are backed by a number of studies:
In the brain, glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as orforglipron protect against nerve damage and enhance the transmission of nerve signals. This in turn can improve various cognitive functions including learning and memory.
Studies show that orforglipron and GLP-1RAs offer protection against neurodegenerative brain disorders and other conditions that can lead to cognitive decline:
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as orforglipron appear to have cardioprotective properties likely via modification of metabolic parameters such as blood sugar control and weight loss. In addition, orforglipron can also improve heart health and protect against heart disease by increasing the secretion of natriuretic peptides which help maintain cardiovascular homeostasis or balance.
The cardioprotective properties of GLP-1RAs are supported by several studies:
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as orforglipron are also essential for liver health. By decreasing the production of blood sugar (glucose) and fat content in the liver, GLP-1RAs can help protect against a broad range of liver diseases.
An increasing number of studies suggest that GLP-1RAs are vital for optimum liver health:
Orforglipron side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on orforglipron. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of orforglipron. Despite this, it was listed as a side effect associated with orforglipron even though these associated side effects are very uncommon.
Side effects associated with orforglipron may include the following:
At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer
I am now in my mid-sixties and feel better than I did in my 20’s. Many people have commented that I actually look 20 years younger since I started the program at Genemedics.
Calling Dr. George has proven to be one of the best decisions I have made in my life. Doctors and society convince us that developing various health issues and negative sy...
Pamela Hill ,66 yrs old
Call 800-277-4041 for a Free Consultation
Genemedics® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.
STEPS AWAY FROM A YOUNGER. HEALHIER YOU!
Call 800-277-4041 for a Free Consultation